# Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

> **NCT07475403** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Bladder Cancer
- Liquid Biopsy
- Immunotherapy

## Interventions

- **DRUG:** Systemic immunotherapy

## Key facts

- **NCT ID:** NCT07475403
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07475403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07475403, "Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07475403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*